Omentin-1 vs DADLE
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and DADLE ([D-Ala2, D-Leu5]-enkephalin) — benefits, dosing, side effects, research data, and where to buy.
| Property | Omentin-1 | DADLE |
|---|---|---|
| Category | Diabetes & Metabolic | Pain Management |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | [D-Ala2, D-Leu5]-enkephalin |
| Molecular Weight | ~35 kDa | 569.67 Da |
| Half-Life | hours | 5-20 minutes in plasma |
| Amino Acids | 313 | 5 |
| Typical Dose | No approved human dose; research use only | 0.01-2 ug per animal |
| Route | IV|SC | Intrathecal / intracerebroventricular |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 450 |
| Research Status | Pre-clinical | Pre-clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
DADLE Benefits
- ✓delta-opioid agonism
- ✓enhanced peptide stability
- ✓spinal analgesia models
- ✓research on tolerance mechanisms
Omentin-1 Dosing
not established|not established
DADLE Dosing
Intrathecal 0.01-2 ug per animal|Intracerebroventricular 0.01-1 ug per animal|In vitro 0.1-50 nM
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
DADLE Side Effects
- ⚠sedation
- ⚠motor suppression at higher doses
- ⚠opioid tolerance with repeated exposure
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
DADLE
DADLE has been studied for analgesic, neuroprotective, and receptor-selective opioid effects in animal and tissue models. It remains important as a mechanistic probe because it is more stable than endogenous enkephalins but still peptide-like in its delivery constraints.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.